Johnson & Johnson has plenty of money coming in from overseas, thanks to U.S. tax reform. But it won’t be spending it on Pfizer’s consumer health unit.
The New Jersey drugmaker has dropped out of the running ahead of the deadline to submit nonbinding offers, J&J confirmed Thursday.
“While we would normally not comment on market speculation or rumors, in this instance we refute assertions that we are in negotiation for Pfizer’s consumer business,” J&J VP of media relations told FiercePharma.
J&J, which snapped up Pfizer’s previous consumer health business for a cool $16.6 billion back in 2006, was considered a viable candidate for the current unit, and it’s about to bring home $12 million in overseas cash thanks to new U.S. tax laws. But earlier this week, CEO Alex Gorsky told investors the company would put a good chunk of that change back into R&D, reminding them that J&J did more than $35 billion in deals last year.
Meanwhile, J&J stepping out of the picture could open things up for GlaxoSmithKline and Reckitt Benckiser, both of which have their eye on the consumer unit. And it could also hurt Pfizer’s negotiating power in the company’s efforts to generate more than $20 billion from a sale, Reuters’ sources said.
That’s not to say there isn’t other competition out there. As one source told Reuters, Pfizer is likely to field five or six bids, and food giant Nestle—which is pushing deeper into the healthcare space to diversify away from its food business—is among them. Bids are due Feb. 1, the news service reports. Earlier this month, reports listed the Swiss company as the frontrunner in the race for Merck KGaA’s OTC unit, which is also up for sale.
By Carly Helfand
Source: Fierce Pharma
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.